Clinical Trial: The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Brief Summary: Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Detailed Summary:
Sponsor: Gachon University Gil Medical Center

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Gachon University Gil Medical Center

Dates:
Date Received: January 25, 2011
Date Started: September 2007
Date Completion:
Last Updated: January 25, 2011
Last Verified: May 2010